What kind of medicine is budesonide sustained-release capsule? Is it currently on the market?

Budesonide sustained-release capsules, as an emerging corticosteroid drug, have attracted widespread attention in the medical community, especially in the field of gastrointestinal disease treatment. The core ingredient of this drug - Budesonide - is a corticosteroid with excellent anti-inflammatory effects. It has a high glucocorticoid effect and a weak mineralocorticoid effect. It shows extremely high affinity for the glucocorticoid receptor. Its affinity is about 200 times that of cortisol and 15 times that of prednisolone. This characteristic gives budesonide sustained-release capsules powerful therapeutic advantages.

Specifically, budesonide extended-release capsules are designed for the treatment of mild to moderately active Crohn's disease affecting the ileum and/or ascending colon in patients 8 years of age and older. Crohn's disease, a chronic inflammatory bowel disease, often causes patients to suffer from diarrhea, abdominal pain, weight loss and other symptoms. The emergence of budesonide sustained-release capsules undoubtedly brings new treatment hope to these patients. Not only that, the drug can effectively maintain clinical remission in adults with mild to moderate Crohn's disease (involving the ileum and/or ascending colon) for up to 3 months, providing patients with a more durable and stable therapeutic effect.

However, it is worth noting that although budesonide sustained-release capsules have been approved for marketing overseas and provide treatment options for overseas patients, this drug has not yet been officially launched in the domestic market. This undoubtedly increases the difficulty and challenge of purchasing drugs for domestic patients who are eager to be treated with this drug. However, domestic patients can still obtain budesonide sustained-release capsules through some formal and legal channels. This can include seeking help from relatives and friends overseas, or consulting professional overseas medical institutions to ensure the authenticity and safety of the purchased medicines and avoid unnecessary risks caused by improper purchase of medicines.

In short, budesonide sustained-release capsules, as an innovative corticosteroid drug, bring new treatment hope and options to patients with Crohn's disease. Although there are still some inconveniences for domestic patients to purchase drugs, with the deepening of international medical exchanges and the continuous improvement of drug approval processes, we have reason to believe that more high-quality drugs like budesonide sustained-release capsules will enter the domestic market in the future, bringing good news to the majority of patients.

Reference materials:https://www.drugs.com/pro/entocort-ec.html#s-34090-1

xa0